Bicycle Therapeutics plc (NASDAQ:BCYC) Stock Position Trimmed by Tybourne Capital Management HK Ltd.

Tybourne Capital Management HK Ltd. cut its position in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 9.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,269,535 shares of the company's stock after selling 125,000 shares during the quarter. Bicycle Therapeutics makes up about 4.5% of Tybourne Capital Management HK Ltd.'s holdings, making the stock its 9th biggest position. Tybourne Capital Management HK Ltd. owned approximately 1.84% of Bicycle Therapeutics worth $17,773,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BCYC. Barclays PLC increased its position in shares of Bicycle Therapeutics by 878.3% during the 4th quarter. Barclays PLC now owns 2,612 shares of the company's stock valued at $37,000 after purchasing an additional 2,345 shares during the last quarter. Avior Wealth Management LLC purchased a new position in Bicycle Therapeutics in the fourth quarter valued at approximately $57,000. JPMorgan Chase & Co. lifted its stake in Bicycle Therapeutics by 26.8% in the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock valued at $191,000 after purchasing an additional 1,782 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Bicycle Therapeutics by 30.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company's stock valued at $131,000 after purchasing an additional 2,191 shares during the last quarter. Finally, Jane Street Group LLC lifted its stake in Bicycle Therapeutics by 18.9% in the fourth quarter. Jane Street Group LLC now owns 23,991 shares of the company's stock valued at $336,000 after purchasing an additional 3,811 shares during the last quarter. 86.15% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on BCYC. Morgan Stanley set a $17.00 price objective on Bicycle Therapeutics and gave the company an "equal weight" rating in a research note on Monday, May 5th. Barclays dropped their price objective on Bicycle Therapeutics from $40.00 to $15.00 and set an "overweight" rating on the stock in a research note on Thursday, May 1st. JMP Securities reduced their target price on shares of Bicycle Therapeutics from $26.00 to $22.00 and set a "market outperform" rating for the company in a research note on Friday, May 2nd. Royal Bank of Canada reduced their target price on shares of Bicycle Therapeutics from $35.00 to $32.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Finally, B. Riley reduced their target price on shares of Bicycle Therapeutics from $17.00 to $14.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $25.00.

Bicycle Therapeutics Stock Down 0.6%

BCYC traded down $0.05 during trading on Friday, reaching $8.05. 132,034 shares of the company were exchanged, compared to its average volume of 397,200. The company's 50-day moving average is $8.08 and its two-hundred day moving average is $12.74. The company has a market cap of $557.49 million, a price-to-earnings ratio of -2.45 and a beta of 1.60. Bicycle Therapeutics plc has a 12-month low of $6.10 and a 12-month high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). The company had revenue of $9.98 million for the quarter, compared to analysts' expectations of $8.67 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. Equities analysts forecast that Bicycle Therapeutics plc will post -3.06 earnings per share for the current year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.